+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07219849

Evaluating the Best Dose and Frequency of ALDP001 Nasal Spray for Adults with Seasonal Allergic Rhinitis

Led by Alixer Nexgen Therapeutics Limited · Updated on 2025-10-22

164

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of ALDP001 Nasal Spray in adults with seasonal allergic rhinitis, a condition characterized by seasonal nasal allergy symptoms caused by ragweed pollen. This Phase 2 study aims to find the best dose and frequency of this nasal spray to help manage symptoms during allergen exposure. The study has two parts. In Part A, participants will use the nasal spray once daily for eight days to determine the optimal dose. After an interim analysis, Part B will have participants use the selected dose twice daily for another eight days to evaluate the best dosing frequency. Participants will self-administer one spray in each nostril either once or twice daily using the provided nasal spray kit. During the study, researchers will monitor symptom changes using the Total Nasal Symptom Score from baseline to Day 9. Other assessments include symptom area under the curve measurements. Participants will undergo health evaluations including medical history, physical exams, vital signs, ECG, and lab tests to ensure safety. The study includes both placebo and experimental groups and is expected to run until April 2026.

CONDITIONS

Brief Title

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

Research Team

A

Akhilesh Sharma

Y

Yogesh Rane

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here